Download PDF
Drug Res (Stuttg) 2024; 74(03): 123-132
DOI: 10.1055/a-2237-8566
Review

Encyclopaedic Review of Glipizide Pre-clinical and Clinical Status

Saad Mohammad
1   Faculty of Pharmacy, Integral University, Lucknow, Uttar Pradesh, India
,
Tarique Mahmood
1   Faculty of Pharmacy, Integral University, Lucknow, Uttar Pradesh, India
,
Arshiya Shamim
1   Faculty of Pharmacy, Integral University, Lucknow, Uttar Pradesh, India
,
Farogh Ahsan
1   Faculty of Pharmacy, Integral University, Lucknow, Uttar Pradesh, India
,
Mohammad Shariq
1   Faculty of Pharmacy, Integral University, Lucknow, Uttar Pradesh, India
,
Saba Parveen
1   Faculty of Pharmacy, Integral University, Lucknow, Uttar Pradesh, India
,
Rufaida Waseem
1   Faculty of Pharmacy, Integral University, Lucknow, Uttar Pradesh, India
,
Aditya Singh
1   Faculty of Pharmacy, Integral University, Lucknow, Uttar Pradesh, India
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Corrected by:

Correction: Encyclopaedic Review of Glipizide Pre-clinical and Clinical StatusDrug Res (Stuttg) 2024; 74(03): e2-e2
DOI: 10.1055/a-2321-8886

Abstract

Glipizide is an oral glucose-lowering medication that is beneficial for the treatment of type 2 diabetes. This study compiles exhaustively all accessible information on glipizide, from preclinical to clinical studies. Glipizide may be used in concert with TRAIL to treat cancer cells; in vitro studies have shown that it suppresses angiogenesis and vasculogenesis while shielding cells from glycation-induced damage. Anticonvulsant effects and modifications in the pharmacokinetics of other medications, such as Divalproex Sodium, were seen in glipizide in vivo experiments. Propranolol amplifies glipizide's hypoglycemic effect briefly in normal animals but consistently enhances it in diabetic ones. In the treatment of cancer and neurodegenerative poly(Q) illnesses, glipizide has demonstrated to offer potential therapeutic advantages. It is ineffective in preventing DENA-induced liver cancer and may cause DNA damage over time. The way glipizide interacts with genetic variants may increase the risk of hypoglycemia. Combining Syzygium cumini and ARBE to glipizide may enhance glycemic and lipid control in type 2 diabetes. Individuals with coronary artery disease who take glipizide or glyburide have an increased risk of death. The risk of muscular responses and acute pancreatitis is minimal when glipizide and dulaglutide are combined. In conclusion, glipizide has shown promising therapeutic efficacy across a variety of disorders.

Keywords

pharmacology - insulin / glucagons - drug research - antidiabetic drugs


Publication History

Received: 11 July 2023

Accepted: 01 January 2024

Article published online:
26 February 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Fischer JGCR. Analogue-based Drug Discovery. In. John Wiley & Sons; 2006: 449
    CrossrefGoogle Scholar
  • 2 Liu H, Zhang B, Chen Y. et al. Novel microporous resin-based polymer device for sustained glipizide release: Production, characterization and pharmacokinetic study. Biomedicine & Pharmacotherapy 2022; 155: 113772 DOI: 10.1016/j.biopha.2022.113772.
    CrossrefPubMedGoogle Scholar
  • 3 Dasgupta D, Patel A. A sustainable nano drug delivery system for poorly soluble drug, glipizide: design, in vitro controlled release and kinetics. Mater Adv 2022; 3: 8220-8228 DOI: 10.1039/D2MA00627H.
    CrossrefPubMedGoogle Scholar
  • 4 Kalam MA, Alshamsan A, Alkholief M. et al. Solubility Measurement and Various Solubility Parameters of Glipizide in Different Neat Solvents. ACS Omega 2020; 5: 1708-1716 DOI: 10.1021/acsomega.9b04004.
    CrossrefPubMedGoogle Scholar
  • 5 Whalen K. Lippincott® Illustrated Reviews: Pharmacology. Wolters kluwer india Pvt Ltd;. 2018
    PubMedGoogle Scholar
  • 6 Shoaib A, Salem-Bekhit MM, Siddiqui HH. et al. Antidiabetic activity of standardized dried tubers extract of Aconitum napellus in streptozotocin-induced diabetic rats. 3 Biotech 2020; 10: 56 DOI: 10.1007/s13205-019-2043-7.
    CrossrefPubMedGoogle Scholar
  • 7 Tiwari R, Siddiqui MH, Mahmood T. et al. Herbal Remedies: A Boon for Diabetic Neuropathy. Journal of Dietary Supplements 2019; 16: 470-490 DOI: 10.1080/19390211.2018.1441203.
    CrossrefPubMedGoogle Scholar
  • 8 Pandey S, Shaif M, Ansari TM. et al. Leveraging Potential of Nanotherapeutics in Management of Diabetic Foot Ulcer. Exp Clin Endocrinol Diabetes 2022; 130: 678-686 DOI: 10.1055/a-1749-4909.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Bruni G, Ghione I, Berbenni V. et al. The Physico-Chemical Properties of Glipizide: New Findings. Molecules 2021; 26: 3142 DOI: 10.3390/molecules26113142.
    CrossrefPubMedGoogle Scholar
  • 10 Song D-K, Ashcroft FM. Glimepiride block of cloned β-cell, cardiac and smooth muscle KATP channels. British Journal of Pharmacology 2001; 133: 193-199 DOI: 10.1038/sj.bjp.0704062.
    CrossrefPubMedGoogle Scholar
  • 11 Ashcroft FM, Rorsman P. Electrophysiology of the pancreatic β-cell. Progress in Biophysics and Molecular Biology 1989; 54: 87-143 DOI: 10.1016/0079-6107(89)90013-8.
    CrossrefPubMedGoogle Scholar
  • 12 Renström E, Barg S, Thévenod F. et al. Sulfonylurea-Mediated Stimulation of Insulin Exocytosis via an ATP-Sensitive K+ Channel–Independent Action. Diabetes 2002; 51: S33-S36 DOI: 10.2337/diabetes.51.2007.S33.
    CrossrefPubMedGoogle Scholar
  • 13 Zhang C-L, Katoh M, Shibasaki T. et al. The cAMP Sensor Epac2 Is a Direct Target of Antidiabetic Sulfonylurea Drugs. Science 2009; 325: 607-610 DOI: 10.1126/science.1172256.
    CrossrefPubMedGoogle Scholar
  • 14 Cevik M, Caker S, Deliorman G. et al. The effects of glipizide on DNA damage and nuclear transport in differentiated 3T3-L1 adipocytes. Molecular Biology Reports 2022; 49: 1151-1159 DOI: 10.1007/s11033-021-06942-5.
    CrossrefPubMedGoogle Scholar
  • 15 Wasim R, Ansari TM, Siddiqui MH. et al. Repurposing of Drugs for Cardiometabolic Disorders: An Out and Out Cumulation. Horm Metab Res 2023; 55: 7-24 DOI: 10.1055/a-1971-6965.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Chen L, Li JH, Kaur V. et al. The presence of two reduced function variants in CYP2C9 influences the acute response to glipizide. Diabet Med 2020; 37: 2124-2130 DOI: 10.1111/dme.14176.
    CrossrefPubMedGoogle Scholar
  • 17 Liu X-H, Li X-M, Han C-C. et al. Effects of combined therapy with glipizide and Aralia root bark extract on glycemic control and lipid profiles in patients with type 2 diabetes mellitus. J Sci Food Agric 2015; 95: 739-744 DOI: 10.1002/jsfa.6829.
    CrossrefPubMedGoogle Scholar
  • 18 Klein-Schwartz W, Stassinos GL, Isbister GK. Treatment of sulfonylurea and insulin overdose: Toxicity and treatment of hypoglycaemic overdose. Br J Clin Pharmacol 2016; 81: 496-504 DOI: 10.1111/bcp.12822.
    CrossrefPubMedGoogle Scholar
  • 19 Gu Q, Wang C, Wang G. et al. Glipizide suppresses embryonic vasculogenesis and angiogenesis through targeting natriuretic peptide receptor A. Experimental Cell Research 2015; 333: 261-272 DOI: 10.1016/j.yexcr.2015.03.012.
    CrossrefPubMedGoogle Scholar
  • 20 Adeshara K, Tupe R. Antiglycation and cell protective actions of metformin and glipizide in erythrocytes and monocytes. Molecular Biology Reports 2016; 43: 195-205 DOI: 10.1007/s11033-016-3947-5.
    CrossrefPubMedGoogle Scholar
  • 21 Qi C, Zhou Q, Li B. et al. Glipizide, an antidiabetic drug, suppresses tumor growth and metastasis by inhibiting angiogenesis. Oncotarget 2014; 5: 9966-9979 DOI: 10.18632/oncotarget.2483.
    CrossrefPubMedGoogle Scholar
  • 22 Nazim UMD, Moon J-H, Lee Y-J. et al. Glipizide sensitizes lung cancer cells to TRAIL-induced apoptosis via Akt/mTOR/autophagy pathways. Oncotarget 2017; 8: 100021-100033 DOI: 10.18632/oncotarget.21754.
    CrossrefPubMedGoogle Scholar
  • 23 Banstola A, Nagalkashmi NC, Swomy SK. et al. USE OF IN VIVO ANIMAL MODELS TO ASSESS THE EFFECT OF GLIPIZIDE ON PHARMACOKINETIC AND ANTICONVULSANT ACTIVITY OF DIVALPROEX SODIUM. World Journal of Pharmacy and Pharmaceutical Sciences 2014; 3: 850–860
    PubMedGoogle Scholar
  • 24 Shinde NG, Aloorkar NH, Bangar BN. et al. Effect Of Propranolol, Glipizide And Its Combination On Blood Glucose Level In Experimental. Animal (MICE) 2013; 2: 253–257
    PubMedGoogle Scholar
  • 25 Prajapati AR, Patel BK, Patel PM. Effects of atenolol and nebivolol alone and combination with glipizide on glucose levels in normal and stz induced diabetic rats. The International Journal of Pharmaceutical Research and Bio-Science 2012; 1: 533–542
    PubMedGoogle Scholar
  • 26 Kim C-H, Park S-H, Sim Y-B. et al. Effect of tolbutamide, glyburide and glipizide administered supraspinally on CA3 hippocampal neuronal cell death and hyperglycemia induced by kainic acid in mice. Brain Research 2014; 1564: 33-40 DOI: 10.1016/j.brainres.2014.03.046.
    CrossrefPubMedGoogle Scholar
  • 27 Kumar VSH, Sindhu NR, Patil RS. et al. Anti-hyperglycemic activity of simvastatin alone (therapeutic dose) and combination of simvastatin and glipizide (sub therapeutic doses) on alloxan induced hyperglycemia in albino rats. International Journal of Pharmaceutical Sciences and Research 2012; 3: 4398
    PubMedGoogle Scholar
  • 28 Haribabu T, Divakar DK, Goli DD. Evaluation of anti-diabetic activity of Lycopene and its synergistic effect with Metformin hydrochloride and Glipizide in Alloxan induced diabetes in rats.
    PubMed
  • 29 Gholve R, Shep D, Gade P. et al. A study on drug-drug interaction between glipizide and cimetidine in rabbits. Int J Curr Pharm Sci 2021; 17-18 DOI: 10.22159/ijcpr.2021v13i2.41545.
    CrossrefPubMedGoogle Scholar
  • 30 Gupta GDRAAATMMCDK, Dua K. Negative effect of glipizide on n-nitrosodiethylamine initiated hepatocellular carcinoma. in: healthcare professionals: scope and opportunities. Amity Insititute of Pharmacy 2020; 100-106
    PubMedGoogle Scholar
  • 31 Abdel-Moneim A-MH, Lutfi MF, Alsharidah AS. et al. Short-Term Treatment of Metformin and Glipizide on Oxidative Stress, Lipid Profile and Renal Function in a Rat Model with Diabetes Mellitus. Applied Sciences 2022; 12: 2019 DOI: 10.3390/app12042019.
    CrossrefPubMedGoogle Scholar
  • 32 Mao G, Zheng S, Li J. et al. Glipizide Combined with ANP Suppresses Breast Cancer Growth and Metastasis by Inhibiting Angiogenesis through VEGF/VEGFR2 Signaling. ACAMC 2022; 22: 1735-1741 DOI: 10.2174/1871520621666210910085733.
    CrossrefPubMedGoogle Scholar
  • 33 Qi C, Bin L, Yang Y. et al. Glipizide suppresses prostate cancer progression in the TRAMP model by inhibiting angiogenesis. Sci Rep 2016; 6: 27819 DOI: 10.1038/srep27819.
    CrossrefPubMedGoogle Scholar
  • 34 Sundhani E, Nugroho AE, Nurrochmad A. et al. Pharmacokinetic Herb-Drug Interactions of Glipizide with Andrographis paniculata (Burm. f.) and Andrographolide in Normal and Diabetic Rats by Validated HPLC Method. Molecules 2022; 27: 6901 DOI: 10.3390/molecules27206901.
    CrossrefPubMedGoogle Scholar
  • 35 Tandon S, Sarkar S. Glipizide ameliorates human poly(Q) mediated neurotoxicity by upregulating insulin signalling in Drosophila disease models. Biochemical and Biophysical Research Communications 2023; 645: 88-96 DOI: 10.1016/j.bbrc.2023.01.022.
    CrossrefPubMedGoogle Scholar
  • 36 Palaksha M, Mani TT, Manjunatha E. et al. Comparative study of In-Vivo effects of Glipizide and Metformin HCl on plasma concentration of Aminophylline in healthy rabbits. Asian Jour Pharmac Rese 2020; 10: 62 DOI: 10.5958/2231-5691.2020.00012.X.
    CrossrefPubMedGoogle Scholar
  • 37 Anusha A, Narendar D, Krishna Murthy B. et al. Influence of Single and Multi Dose Treatment of Glipizide on Pharmacokinetics and Pharmacodynamics of Irbesartan in Normal and Hypertensive Rats. High Blood Press Cardiovasc Prev 2017; 24: 179-185 DOI: 10.1007/s40292-017-0195-2.
    CrossrefPubMedGoogle Scholar
  • 38 Ju E, So O, Sk L. et al. Comparative Studies on Safety of Glimepiride and Glipizide on Renal Microarchitecture and Oxidative Stress Markers of Pregnant Streptozotocin-Induced Diabetic Wistar Rats. J Pharm Pharmacol Res 2019; 03 DOI: 10.26502/jppr.0016.
    CrossrefPubMedGoogle Scholar
  • 39 Chaudhari S, Zambad S, Ali M. Pharmacokinetic and Pharmacodynamics Interaction between Syzygium cumini and Glipizide: Role of Cytochrome P450 Enzyme. IJPER 2019; 53: s273-s279 DOI: 10.5530/ijper.53.3s.97.
    CrossrefPubMedGoogle Scholar
  • 40 Sujatha DS, Vanishree S, Pingili RB. et al. Influence of lovastatin on pharmacokinetics and pharmacodynamics of glipizide in healthy and streptozotocin - Induced diabetic rats: Involvement of p-glycoprotein inhibition. Asian Journal of Pharmaceutical and Clinical Research 2016; 9: 3-8 DOI: 10.22159/ajpcr.2016.v9i5.1191.
    CrossrefPubMedGoogle Scholar
  • 41 Yang G, Zeng G, Wu JP. et al. Glipizide blocks renal interstitial fibrosis by inhibiting AKT signaling pathway. Eur Rev Med Pharmacol Sci 2017; 21: 867-872
    PubMedGoogle Scholar
  • 42 Rosenstock J, Wilson C, Fleck P. Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study. Diabetes Obes Metab 2013; 15: 906-914 DOI: 10.1111/dom.12102.
    CrossrefPubMedGoogle Scholar
  • 43 Kim N-T, Cho CK, Kang P. et al. Effects of CYP2C9*3 and *13 alleles on the pharmacokinetics and pharmacodynamics of glipizide in healthy Korean subjects. Arch Pharm Res 2022; 45: 114-121 DOI: 10.1007/s12272-021-01366-y.
    CrossrefPubMedGoogle Scholar
  • 44 Yahya Saber EM, Nusieba AMI. A Local Study on the Effect of Glipizide and Metformin as Combination Drugs in the Treatment of Polycystic Ovary Syndrome in El-beida, Libya. PBJ 2019; 01-05 DOI: 10.20510/ukjpb/7/i6/1579095700.
    CrossrefPubMedGoogle Scholar
  • 45 Malam PP, Kantharia ND, Zala AC. et al. Role of glipizide therapy on oxidative stress parameters in the patient with Type-II diabetes mellitus 2014; 3: 995–999
    PubMed
  • 46 Johnston S, Bell K, Thomson E. et al. Comparison of real-world hypoglycemia rates among Patients Initiating Treatment with Saxagliptin or Glipizide. Value in Health 2015; 18: A58 DOI: 10.1016/j.jval.2015.03.338.
    CrossrefPubMedGoogle Scholar
  • 47 Muzahid M, Ahsan R, Khan MI. et al. Saxagliptin: A systematic review on its pharmacological potential and analytical aspects. In:. 2021
    PubMed
  • 48 Arjona Ferreira JC, Marre M, Barzilai N. et al. Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency. Diabetes Care 2013; 36: 1067-1073 DOI: 10.2337/dc12-1365.
    CrossrefPubMedGoogle Scholar
  • 49 Hong J, Zhang Y, Lai S. et al. on behalf of the S-DI. Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Coronary Artery Disease. Diabetes Care 2013; 36: 1304-1311 DOI: 10.2337/dc12-0719.
    CrossrefPubMedGoogle Scholar
  • 50 Del Prato S, Nauck M, Durán-Garcia S. et al. Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data. Diabetes Obes Metab 2015; 17: 581-590 DOI: 10.1111/dom.12459.
    CrossrefPubMedGoogle Scholar
  • 51 Pantalone KM, Kattan MW, Yu C. et al. Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis. Diabetes Obes Metab 2012; 14: 803-809 DOI: 10.1111/j.1463-1326.2012.01604.x.
    CrossrefPubMedGoogle Scholar
  • 52 Srinivasan S, Kaur V, Chamarthi B. et al. TCF7L2 Genetic Variation Augments Incretin Resistance and Influences Response to a Sulfonylurea and Metformin: The Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR-MGH). Diabetes Care 2018; 41: 554-561 DOI: 10.2337/dc17-1386.
    CrossrefPubMedGoogle Scholar
  • 53 Yang Y, Tian X, Huang Y. et al. Clinical Study of Liraglutide Combined with Insulin and Glipizide in the Treatment of Subclinical Hypothy-roidism Complicated with Type 2 Diabetes in the Elderly Patients. China. Pharmacy 2017; 12: 1958-1961
    PubMedGoogle Scholar
  • 54 Singh A, Rai J, Mahajan D. Comparative evaluation of glipizide and fenugreek (Trigonella foenum-graecum) seeds as monotherapy and combination therapy on glycaemic control and lipid profile in patients with type 2 diabetes mellitus. Int J Basic Clin Pharmacol 2016; 5: 942-950 DOI: 10.18203/2319-2003.ijbcp20161549.
    CrossrefPubMedGoogle Scholar
  • 55 Babajide O, K C N Solaimanzadeh I, Shiferaw-Deribe Z. Case Report of Acute Pancreatitis Associated With Combination Treatment of Dulaglutide and Glipizide. Cureus 2022; 14: e20938 DOI: 10.7759/cureus.20938.
    CrossrefPubMedGoogle Scholar
  • 56 Das S, Ramasamy A, De S. et al. An unusual case of glipizide-induced proximal myopathy. Journal of Pharmacology and Pharmacotherapeutics 2016; 7: 99-101 DOI: 10.4103/0976-500X.184775.
    CrossrefPubMedGoogle Scholar
  • 57 Kamal P, Bhabhra R. SUN-185 Glipizide Induced Hepatotoxicity. Journal of the Endocrine Society 2019; 3: SUN-185 DOI: 10.1210/js.2019-SUN-185.
    CrossrefPubMedGoogle Scholar
  • 58 Eliakim-Raz N, Leibovici L, Petach-Tikvah I. Some antimicrobials increased admis-sions and ED visits for hypoglycemia in older users of glipizide or glyburide. Intern Med 2014; 174: 1605-1612
    PubMedGoogle Scholar
  • 59 Göke B, Gallwitz B, Eriksson JG. et al. Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial. Int J Clin Pract 2013; 67: 307-316 DOI: 10.1111/ijcp.12119.
    CrossrefPubMedGoogle Scholar
  • 60 Nauck MA, Del Prato S, Meier JJ. et al. Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin. Diabetes Care 2011; 34: 2015-2022 DOI: 10.2337/dc11-0606.
    CrossrefPubMedGoogle Scholar